950236-50-7Relevant academic research and scientific papers
Phosphodiesterase inhibitory properties of losartan. Design and synthesis of new lead compounds
Segarra, Victor,Crespo, M. Isabel,Pujol, Ferran,Beleta, Jorge,Domenech, Teresa,Miralpeix, Montserrat,Palacios, Jose M.,Castro, Ana,Martinez, Ana
, p. 505 - 510 (1998)
A 4-centre PDE 4 pharmacophore search has been carried out in several 3D-databases containing compounds belonging to different therapeutic areas. Losartan, an angiotensin-II antagonist, has been identified as a new lead compound for developing PDE 4 inhibitors. New families of compounds derived from losartan has been synthesized and their PDE inhibition has been measured.
Synthesis and cytotoxicity screening of piperazine-1-carbodithioate derivatives of 2-substituted quinazolin-4(3H)-ones
Cao, Sheng-Li,Guo, Yan-Wen,Wang, Xian-Bo,Zhang, Mei,Feng, Yu-Ping,Jiang, Yu-Yang,Wang, Yue,Gao, Qian,Ren, Jian
experimental part, p. 182 - 189 (2009/05/26)
A new series of piperazine-1-carbodithioate derivatives of 2-substituted quinazolin-4(3H)-ones were synthesized via a five-steps procedure starting from 2-amino-5-methylbenzoic acid. The cytotoxicity of the resulting compounds against A-549 (human lung ca
